Related Experiment Video

Updated: May 19, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond

Jiyeon Kim1, Seong Hwan Kim

  • 1Laboratory of Translational Therapeutics, Pharmacology Research Center, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon, 305-600, Korea.

Archives of Pharmacal Research
|September 4, 2012
PubMed

Insights

The small molecule inhibitor CX-4945 targets casein kinase 2 (CK2), showing anti-cancer effects by inhibiting cell proliferation, angiogenesis, and inflammation. Its oral bioavailability suggests potential as a novel cancer therapeutic.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Casein kinase 2 (CK2) is crucial for cellular processes like proliferation and cell cycle.
  • CK2 overexpression in cancers correlates with angiogenesis and tumor progression.
  • CX-4945 is the first orally bioavailable small molecule inhibitor of CK2.

Purpose of the Study:

  • To evaluate the anti-cancer potential of CX-4945.
  • To investigate the mechanisms underlying CX-4945's effects on cancer cells and tumor growth.

Main Methods:

  • In vitro studies on human cancer cells.
  • In vivo investigations using mouse xenograft models.
  • Analysis of cell cycle, PI3K/Akt pathway, and inflammatory markers.

Main Results:

  • CX-4945 demonstrated anti-proliferative activity by inhibiting cell cycle and PI3K/Akt signaling.
  • CX-4945 reduced angiogenesis through blockade of hypoxia-inducible factor-1α.
  • CX-4945 suppressed interleukin-6 production in breast cancer cells.

Conclusions:

  • CX-4945 exhibits significant anti-cancer properties through multiple mechanisms.
  • The oral bioavailability and efficacy in preclinical models support CX-4945's development as a cancer drug.
  • Further clinical trials are warranted to establish CX-4945's therapeutic value.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...